TerminatedNo phase
A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)
Reason given: Sponsor decision to terminate; sufficient sample size for statistical analysis has been achieved.
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
Trial details
- Who runs it
- BioMarin Pharmaceutical
- Trial code
- NCT05580692
- Record updated
- 19 August 2024
- Original description
A prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypesRead full original descriptionShow less
A Multinational, Multi-center, Prospective Cohort Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV) Serotypes in Subjects With Hemophilia A
A prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes
Inclusion: Adult Subjects with Hemophilia A.
Exclusion: Subject previously treated with AAV vector gene therapy.